AscellaHealth Showcases End-to-End Specialty Pharmaceutical Commercialisation Solutions at World Orphan Drug Congress, Shapes Future of Rare and Orphan Disease Therapies

Contributed by: Business Wire

Logo

Tags

Health

Infectious Diseases

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

WODC

More Like This

Global End-to-End Solutions Partner to Life Sciences Organisations, AscellaHealth, Joins Manchester Science Park

AscellaHealth Demonstrates Leadership in Realizing the Full Potential of Novel Therapies and Medicinal Products at Advanced Therapies Integrates North 2025

AscellaHealth Supports Rare Disease Patients and Caregivers in Observance of Rare Disease Day, February 28

(Photo: Business Wire)

AscellaHealth Expands Global Leadership Team: Specialty Pharmaceutical Experts with Manufacturer and Payer Expertise Propel International Growth

AscellaHealth Identifies Key Health Trends for 2024: Forecasts Robust Outlook for Specialty Pharmacy Industry

AscellaHealth Podcast Pulse: AscellaHealth Launches Podcast Series Addressing Key Issues Impacting Life Sciences & Payers within the Specialty Healthcare Ecosystem

AscellaHealth Announces its Strategic Acquisition of CHAPPER healthcare: Expands Global Specialty Pharmaceutical Wholesale and Product Distribution Services

PR Newswire associated0

Advanced Therapies Europe 2025 unveils a reimagined, high-impact format: capped at 500, curated for connection